GlassScriptPhysician profile
Vanessa Bostwick
NPI 1609346147
$3,358.64
in general payments reported to CMS, 2019-2025
23 companies · $610 in 2025
The $610 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $881 · 2022: $777 · 2023: $504 · 2024: $586 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.04 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $712.33 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $349.01 | 2022-2024 | Reblozyl |
| Kite Pharma, INC. | $314.96 | 2022-2025 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $264.60 | 2021-2024 | Calquence, Enhertu |
| Glaxosmithkline, LLC. | $249.91 | 2021-2022 | |
| Genentech, INC. | $177.45 | 2021 | |
| Pfizer INC. | $155.25 | 2023-2025 | |
| Janssen Biotech, INC. | $133.60 | 2025 | Carvykti, Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2024 | Iclusig |
| Adc Therapeutics America, INC. | $121.26 | 2021 | |
| Incyte Corporation | $118.36 | 2022-2025 | Niktimvo, Jakafi |
| Genmab U.S., INC. | $112.32 | 2024 | Epkinly |
| Karyopharm Therapeutics INC. | $109.65 | 2022 | |
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Gilead Sciences, INC. | $82.72 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46.03 | 2021-2025 | |
| Genentech USA, INC. | $41.74 | 2025 | Venclexta |
| Merck Sharp & Dohme LLC | $36.80 | 2025 | Prevymis |
| Beone Medicines USA, INC. | $25.84 | 2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $25.58 | 2025 | Ultomiris |
| Cycle Pharmaceuticals INC | $24.82 | 2025 | Phyrago |
| Tempus Ai, INC | $24.74 | 2025 | Xt Cdx |
| Janssen Scientific Affairs, LLC | $16.72 | 2024 | Darzalex, Tecvayli, Talvey |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Bostwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.